PL368897A1 - Kompozycje farmaceutyczne do leczenia astmy - Google Patents

Kompozycje farmaceutyczne do leczenia astmy

Info

Publication number
PL368897A1
PL368897A1 PL02368897A PL36889702A PL368897A1 PL 368897 A1 PL368897 A1 PL 368897A1 PL 02368897 A PL02368897 A PL 02368897A PL 36889702 A PL36889702 A PL 36889702A PL 368897 A1 PL368897 A1 PL 368897A1
Authority
PL
Poland
Prior art keywords
asthma
treatment
pharmaceutical compositions
processes
relates
Prior art date
Application number
PL02368897A
Other languages
English (en)
Other versions
PL209640B1 (pl
Inventor
Joel A. Sequeira
Stefan A. Sharpe
John L. Hart
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23224164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL368897(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of PL368897A1 publication Critical patent/PL368897A1/pl
Publication of PL209640B1 publication Critical patent/PL209640B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL368897A 2001-08-28 2002-08-27 Inhalator z odmierzaną dawką zawierający aerozolowy zawiesinowy preparat, sposób wytwarzania takiego preparatu i jego zastosowanie PL209640B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31538601P 2001-08-28 2001-08-28

Publications (2)

Publication Number Publication Date
PL368897A1 true PL368897A1 (pl) 2005-04-04
PL209640B1 PL209640B1 (pl) 2011-09-30

Family

ID=23224164

Family Applications (1)

Application Number Title Priority Date Filing Date
PL368897A PL209640B1 (pl) 2001-08-28 2002-08-27 Inhalator z odmierzaną dawką zawierający aerozolowy zawiesinowy preparat, sposób wytwarzania takiego preparatu i jego zastosowanie

Country Status (26)

Country Link
US (3) US20030114428A1 (pl)
EP (3) EP2319494B1 (pl)
JP (3) JP2005502675A (pl)
KR (1) KR100970531B1 (pl)
CN (2) CN101856362A (pl)
AR (1) AR036358A1 (pl)
AT (2) ATE503461T1 (pl)
AU (1) AU2002313828B2 (pl)
BR (1) BR0212089A (pl)
CA (1) CA2457926A1 (pl)
CO (1) CO5560551A2 (pl)
CY (2) CY1109212T1 (pl)
DE (2) DE60232251D1 (pl)
DK (2) DK2092935T3 (pl)
ES (3) ES2361805T3 (pl)
HU (1) HUP0401514A3 (pl)
MX (1) MXPA04001875A (pl)
NO (1) NO20041277L (pl)
NZ (1) NZ530987A (pl)
PE (1) PE20030390A1 (pl)
PL (1) PL209640B1 (pl)
PT (2) PT1420759E (pl)
SI (2) SI2092935T1 (pl)
TW (1) TWI324934B (pl)
WO (1) WO2003020253A2 (pl)
ZA (1) ZA200401419B (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
PT1372608E (pt) * 2001-03-30 2008-01-04 Jagotec Ag Formulações de aerossol médicas
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1785156B1 (en) * 2002-08-23 2012-06-27 Schering Corporation Metered dose inhaler containing an aerosol suspension formulation
CA2495689A1 (en) * 2002-08-23 2004-03-04 Schering Corporation Pharmaceutical compositions
ATE384001T1 (de) * 2002-08-27 2008-02-15 Schering Corp Verfahren zur herstellung von dosierinhalatorformulierungen
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1925293A3 (en) * 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
CN1870976A (zh) * 2003-10-20 2006-11-29 先灵公司 药物组合物
PT1711164E (pt) * 2004-01-21 2010-06-28 Schering Corp Método de tratamento da rinossinusite aguda
US20110053999A1 (en) * 2004-03-03 2011-03-03 Daley Thomas E 4-methylpyrazole formulations for inhibiting ethanol intolerance
AU2005293328B2 (en) * 2004-10-12 2010-09-30 Generics (Uk) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
MX2007012084A (es) 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
EP1981545A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations
WO2008097233A1 (en) * 2007-02-09 2008-08-14 Schering Corporation Stable pharmaceutical drug aerosols
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
GB0714239D0 (en) * 2007-07-20 2007-08-29 Glaxo Group Ltd Method
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
JP2011509936A (ja) * 2008-01-10 2011-03-31 シェーリング コーポレイション 吸入薬物製品、システムおよび使用
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
EP2414560B1 (de) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Verfahren zur beschichtung einer oberfläche eines bauteils
US9265910B2 (en) 2009-05-18 2016-02-23 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and nebulizer
SI3106149T1 (sl) * 2009-05-29 2020-07-31 Pearl Therapeutics, Inc. Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
WO2011027247A1 (en) 2009-09-03 2011-03-10 Sulur Subramaniam Vanangamudi An antifungal cream comprising terbinafine hydrochloride
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
CA2781792C (en) 2009-11-25 2019-04-02 Boehringer Ingelheim International Gmbh Nebulizer
EP3300732A1 (en) * 2009-12-07 2018-04-04 Horizon Orphan LLC 4-methylpyrazole formulations
WO2011101830A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and clobetasone, and a process to make it
WO2011101828A1 (en) 2010-02-22 2011-08-25 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sidium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
EP2585151B1 (en) 2010-06-24 2018-04-04 Boehringer Ingelheim International GmbH Nebulizer
WO2012017368A1 (en) 2010-08-02 2012-02-09 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, beclomethasone dipropionate and a process to make it
WO2012049543A1 (en) 2010-10-15 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a corticosteroid, and a process to make it
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
ES2704465T3 (es) * 2011-10-11 2019-03-18 Chiesi Farm Spa Micropartículas cristalinas de un agonista de beta recubierto con un ácido graso
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
HK1219059A1 (zh) 2013-03-15 2017-03-24 珍珠治疗公司 用於微粒晶体材料的状态调节的方法和系统
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
BR112016023983B1 (pt) 2014-05-07 2022-10-18 Boehringer Ingelheim International Gmbh Contentor para um nebulizador, nebulizador para um fluido e método para conectar um contentor a um dispositivo indicador
WO2015169430A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Nebulizer
SG11201608891RA (en) 2014-05-07 2016-11-29 Boehringer Ingelheim Int Nebulizer, indicator device and container
US9360400B2 (en) 2014-06-30 2016-06-07 Proveris Scientific Corporation Sampling apparatus for determining the amount and uniformity of a delivered dose of drug and related methods
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2017093758A1 (en) 2015-12-04 2017-06-08 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
WO2017156287A1 (en) * 2016-03-09 2017-09-14 Proveris Scientific Corporation Methods for measuring dose content uniformity performance of inhaler and nasal devices
CN106619658B (zh) * 2016-12-28 2022-02-08 四川普锐特药业有限公司 一种医用气溶胶制剂及定量吸入气雾剂
US20210338626A1 (en) 2020-04-28 2021-11-04 Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch Methods for treating or preventing a viral infection or inhibiting viral replication
WO2022081847A1 (en) 2020-10-15 2022-04-21 Proveris Scientific Corporation Systems and methods for inhaler testing

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
US5474759A (en) * 1991-06-10 1995-12-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations
US6250300B1 (en) * 1992-12-11 2001-06-26 Ab Astra System for dispensing pharmaceutically active compounds
CN1088580C (zh) * 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
CN1162157C (zh) * 1996-08-29 2004-08-18 先灵公司 无氯氟烃的糠酸莫米他松气溶胶制剂
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US6503537B2 (en) * 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
WO2000030654A1 (en) * 1998-11-26 2000-06-02 Britannia Pharmaceuticals Limited Anti-asthmatic combinations comprising surface active phospholipids
AR022695A1 (es) * 1999-01-28 2002-09-04 Schering Corp PORTADOR SoLIDO PARTICULADO Y MÉTODO PARA PROVEER CONTROL DE LA PARTICULADA PARA LA DISTRIBUCIoN DE TAMANO DE PARTíCULAS Y DE CONTENIDO AMORFO CONVERTIBLE DURANTE SU PREPARACION
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
MXPA02007052A (es) * 2000-01-20 2002-12-13 Basilea Pharmaceutica Ag Composiciones que se administran nasalmente y que contienen peptidos ciclicos.
GB0009612D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic formulations
CA2417973A1 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme

Also Published As

Publication number Publication date
JP5170789B2 (ja) 2013-03-27
HK1060972A1 (en) 2004-09-03
ATE430555T1 (de) 2009-05-15
JP2010138184A (ja) 2010-06-24
HK1128428A1 (en) 2009-10-30
DE60239648D1 (de) 2011-05-12
HUP0401514A2 (hu) 2004-12-28
MXPA04001875A (es) 2004-06-15
SI1420759T1 (sl) 2009-10-31
JP2005502675A (ja) 2005-01-27
JP2009185075A (ja) 2009-08-20
CN101856362A (zh) 2010-10-13
BR0212089A (pt) 2004-08-03
CA2457926A1 (en) 2003-03-13
US20050147565A1 (en) 2005-07-07
NZ530987A (en) 2006-08-31
AR036358A1 (es) 2004-09-01
EP2319494A1 (en) 2011-05-11
WO2003020253A2 (en) 2003-03-13
EP2092935A1 (en) 2009-08-26
HK1151987A1 (en) 2012-02-17
ZA200401419B (en) 2005-01-26
ES2325316T3 (es) 2009-09-01
AU2002313828B2 (en) 2005-09-08
US20100143269A1 (en) 2010-06-10
PL209640B1 (pl) 2011-09-30
CO5560551A2 (es) 2005-09-30
CN1649568A (zh) 2005-08-03
CN1649568B (zh) 2010-10-27
PT1420759E (pt) 2009-06-30
ES2389480T3 (es) 2012-10-26
EP2092935B1 (en) 2011-03-30
US20030114428A1 (en) 2003-06-19
WO2003020253A3 (en) 2003-05-22
EP1420759B1 (en) 2009-05-06
PE20030390A1 (es) 2003-04-24
TWI324934B (en) 2010-05-21
KR20040031002A (ko) 2004-04-09
PT2092935E (pt) 2011-05-31
HUP0401514A3 (en) 2012-08-28
DK2092935T3 (da) 2011-07-18
EP2319494B1 (en) 2012-06-13
EP1420759A2 (en) 2004-05-26
CY1111726T1 (el) 2015-10-07
KR100970531B1 (ko) 2010-07-16
ES2361805T3 (es) 2011-06-22
DK1420759T3 (da) 2009-08-03
DE60232251D1 (de) 2009-06-18
CY1109212T1 (el) 2014-07-02
ATE503461T1 (de) 2011-04-15
SI2092935T1 (sl) 2011-07-29
NO20041277L (no) 2004-03-26

Similar Documents

Publication Publication Date Title
PL368897A1 (pl) Kompozycje farmaceutyczne do leczenia astmy
IL163160A (en) Pharmaceuticals containing Formavertrol, Budsunida, 227hf 'pvp and peg for the treatment or relief of respiratory disorders
GB0129260D0 (en) Pharmaceutical compositions and their uses
IL203923A (en) Benzamide compounds, pharmaceutical compositions comprising them, use thereof in the preparation of medicaments and as medicaments and processes for the preparation of such compounds
EP1399414A4 (en) SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA
HUP0600781A2 (en) Compounds for the treatment of metabolic disorders and pharmaceutical compositions containing them
HUP0201834A3 (en) Use of thyromimetic compounds for the manufacture of a pharmaceutical composition for the treatment of hair loss and such compositions
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
IL157734A0 (en) Pharmaceutical compositions for the treatment of urogenital disorders
MY129422A (en) Medicinal compounds
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
HUP0401086A3 (en) 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for preparation of pharmaceutical compositions for the treatment of pain, anxiety or gastrointestinal disorders and process for preparation the compounds
IL164896A (en) Pharmaceutical compositions comprising immunoconjugates for the treatment of tumors
WO2001053457A3 (en) Vaccines against neurodegenerative disorders
AU2003259986A1 (en) Pharmaceutical compositions
AU3687400A (en) New combination of formoterol and mometasone in a pharmaceutical composition fortreating respiratory disorders, such as asthma, rhinitis and copd
WO2001076601A3 (en) Pharmaceutical compositions comprising salmeterol and ipratropium
WO2003050067A3 (fr) Analogues de la vitamine d
WO2002069979A3 (en) Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
IL168308A (en) Compositions containing roflumilast and formoterol
IL160852A0 (en) Pharmaceutical compositions for the treatment of urinary disorders
IL161091A0 (en) Compositions for the treatment and prevention of plant pathogens
CA2461757A1 (en) Nicotine formulations comprising chocolate and use thereof
IL168307A (en) Compositions containing roflumilast and (r,r)-formoterol
AU2002325687A1 (en) Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20140827